Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
Bartosz Hudzik/LinkedIn
May 22, 2026, 16:28

Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance

Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn:

“At EuroPCR 2026, we are presenting our results:

‘Selecting high-bleeding risk AMI patients with AF for triple antithrombotic therapy after PCI‘

Contemporary antithrombotic management in AF-PCI patients has progressively shifted toward treatment de-escalation, largely driven by concerns surrounding bleeding.

Yet the prevailing paradigm that all high bleeding risk (HBR) patients should uniformly receive abbreviated or simplified regimens deserves reconsideration.

In our cohort of AF patients presenting with STEMI and NSTEMI undergoing PCI, integration of the REDUAL-PCI score with the ARC-HBR trade-off model identified a clinically relevant subgroup in whom ischemic risk remained predominant despite clear HBR features.

Key observations:

  • More than 70% of patients demonstrated a REDUAL-PCI score ≥5
  • These patients had substantially greater ischemic burden, including prior MI, CKD, and complex PCI
  • Ischemic-dominant profiles were threefold more frequent among REDUAL ≥5 patients
  • Estimated MI/stent thrombosis risk substantially exceeded bleeding liability in a significant proportion of HBR patients

The important message is straightforward:

High bleeding risk does not necessarily equate to bleeding-risk predominance.

A growing tendency exists to treat HBR as a therapeutic endpoint rather than as one component of a broader competing-risk equation.

Our data suggest this approach may oversimplify decision-making in AF-PCI patients, particularly in those with advanced atherosclerotic and thrombotic substrates.

The combination of REDUAL-PCI and ARC-HBR trade-off assessment may help identify patients in whom ischemic protection remains critically important and in whom triple antithrombotic therapy should not be dismissed reflexively.

The field likely needs to move beyond standardized de-escalation algorithms toward a more nuanced and personalized antithrombotic strategy — one based not solely on bleeding vulnerability, but on the dynamic balance between bleeding and thrombosis.”

Bartosz Hudzik

Other posts featuring Bartosz Hudzik on Hemostasis Today.

AF Africa STEMI Conference AMI antithrombotic therapy ARC-HBR Bartosz Hudzik bleeding disorders Blood Cardiology CKD EuroPCR 2026 HBR Health Hematology Hemostasis News Hemostasis Today high bleeding risk Medicine NSTEMI PCI thrombosis
NewsFeed